References

AGE-RELATED MACULAR DEGENERATION (AMD)

  1. Augood CA et al. Prevalence of age-related maculopathy in older Europeans. Arch Ophthalmol. 2006; 124: 529-535.
  2. Vision Problems in the US: Prevalence of Adult Vision Impairment and Age-Related Eye Disease in America. 4th ed. Prevent Blindness America, 2008.
  3. Solomon SD et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration (Review). The Cochrane Library. 2014; 8: 1-155.
  4. de Jong P. Age-related macular degeneration. NEJM. 2006; 355(14): 1474-1485.
  5. Ferris FL et al. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102: 1640-1642.
  6. Chopdar A et al. Age related macular degeneration. BMJ. 2003; 326: 485-488.
  7. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002; 15: 142-152.
  8. Williams RA et al. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998; 116: 514-520.
  9. American Academy of Ophthalmology. Preferred Practice Pattern. Age-related macular degeneration. 2015.
  10. Coleman HR et al. Age-related macular degeneration. Lancet. 2008; 372: 1835-1845.
  11. Wong WL et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health. 2014; 2:e106-16.
  12. Fine SL et al. Age-related macular degeneration. NEJM. 2000; 342: 483-492.
  13. Seddon JM et al. The US twin study of age-related macular degeneration. Arch Ophthalmol. 2005; 123: 321-327.
  14. Klein R et al. Ten-year incidence and progression of age-related maculopathy. Ophthalmology. 2002; 109: 1767-1779.
  15. 1Klein R et al. Prevalence of age-related maculopathy. Ophthalmology. 1992; 99: 933-943.
  16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001; 119: 1417-1436.
  17. Moutray T, Chakravarthy U. Age related macular degeneration (AMD): clinical features and clinical management. International Agency for the Prevention of Blindness. 2013.
  18. Kaiser PK. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension TAP Report No. 8. Graefe’s Arch Clin Exp Ophthalmol. 2006; 244: 1132–1142.
  19. LUCENTIS® Summary of Product Characteristics. Novartis AG; Sept. 2015.
  20. Brody BL et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001; 108: 1893-1901.
  21. Mayo Clinic Staff. Lifestyle and home remedies. http://www.mayoclinic.org/diseases-conditions/wetmacular- degeneration/basics/lifestyle-home-remedies/con-20043518 (Accessed March 2016).
  22. Victoria State Government. Better Health Channel. Vision loss and cooking. https://www.betterhealth. vic.gov.au/health/conditionsandtreatments/eyes-vision-loss (Accessed March 2016).

DIABETIC MACULAR EDEMA (DME)

  1. Ciulla TA, et al. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26: 2653-2664.
  2. National Eye Institute. Facts About Diabetic Retinopathy. 2011. http://www.nei.nih.gov/health/diabetic/retinopathy.asp (Accessed March 2016).
  3. Fareed A. A review of diabetic macular edema. Digital Journal of Ophthalmology. 1997; volume 3; number 6.
  4. Watkins PJ. Retinopathy. BMJ. 2003; 326: 924-926.
  5. American Diabetes Association. Living with diabetes. 2011. http://www.diabetes.org/living-withdiabetes/complications/eye-complications/ (AccessedMarch 2016).
  6. Canadian Diabetes Association. Diabetes and you: vision health. 2011. http://www.diabetes.ca/diabetes-and-you/living/complications/vision-health/ (Accessed March 2016).
  7. Royal College of Ophthalmology. Diabetic Retinopathy Guidelines. 2012. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013. pdf (Accessed March 2016).
  8. Varma R, et al. Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States. Ophthalmology. 2015; 122(5):982-989.
  9. Revisiting DME. Available at http://www.retinalphysician.com/printarticle.aspx?articleID=106441(Accessed March 2016).
  10. Eyre H and Kahn R. Preventing cancer, cardiovascular disease, and diabetes. Diabetes Care. 2004; 27: 1812-1824.
  11. National Diabetes Information Clearinghouse. Prevent diabetes problems: Keep your diabetes under control. 2008; NIH Publication No. 08-4349.
  12. Mayo Clinic Staff. Lifestyle and home remedies. http://www.mayoclinic.org/diseases-conditions/wetmacular-degeneration/basics/lifestyle-home-remedies/con-20043518 (Accessed March 2016).
  13. WHO. Fact sheet 312: Diabetes. 2011. Available at http://www.who.int/mediacentre/factsheets/fs312/en (Accessed March 2016).
  14. LUCENTIS® Summary of Product Characteristics. Novartis AG; Sept.
  15. Hariprasad SM, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008; 92: 89-92.
  16. Victoria State Government. Better Health Channel. Vision loss and cooking. https://www.betterhealth. vic.gov.au/health/conditionsandtreatments/eyes-vision-loss (Accessed March 2016).